When does Novo Nordisk report earnings and why does it matter for NOV.DE stock?

Novo Nordisk reports earnings on **2026-02-04**; the release matters because guidance and diabetes/obesity sales will likely drive short-term moves in **NOV.DE stock**.

What is Meyka AI's short-term forecast for NOV.DE stock?

Meyka AI's forecast model projects **€51.97** for the month, implying about **2.91%** upside versus the current **€50.50** price. Forecasts are model projections and not guarantees.

What valuation metrics should investors watch for NOV.DE stock?

Key metrics: **PE 15.87**, **EPS 3.12**, price-to-sales **5.21**, price-to-book **9.69**, and dividend yield **3.15%**; changes in guidance will shift fair-value views for **NOV.DE stock**.

What are the main risks to NOV.DE stock around earnings?

Main risks include weaker-than-expected revenue/guidance, margin pressure, or regulatory news; these could trigger a re-rating of **NOV.DE stock** in the short term.

DE Stocks

Pre-market 30 Jan 2026: NOV.DE Novo Nordisk (XETRA) ahead of Feb 4 earnings: EPS

ByHuzaifa Zahoor January 30, 2026January 30, 2026

We start the pre-market with NOV.DE stock trading at €50.50 as investors focus on the upcoming February 4 earnings release. The company reports after European markets open, and analysts will watch revenue mix, diabetes and obesity growth, and guidance. Novo Nordisk A/S (NOV.DE) trades on XETRA in Germany and shows a trailing PE of 15.87 and EPS of 3.12, metrics investors will weigh against its recent price recovery from the 52-week low.